High expression of nucleoporin 133 mRNA in bone marrow CD138+ cells is a poor prognostic factor in multiple myeloma

Recent advances in plasma cell biology and molecularly-targeted therapy enable us to employ various types of drugs including immunomodulatory drugs, proteasome inhibitors, and immunotherapy. However, the optimal therapeutic strategies to introduce these drugs for heterogeneous patients with multiple...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibata, Soushi, Kobune, Masayoshi, Kikuchi, Shohei, Yoshida, Masahiro, Miura, Shogo, Horiguchi, Hiroto, Murase, Kazuyuki, Iyama, Satoshi, Takada, Kohichi, Miyanishi, Koji, Kato, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982762/
https://www.ncbi.nlm.nih.gov/pubmed/29861858
http://dx.doi.org/10.18632/oncotarget.25350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982762/
https://www.ncbi.nlm.nih.gov/pubmed/29861858
http://dx.doi.org/10.18632/oncotarget.25350

Ejemplares similares